{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:17:05Z","timestamp":1789503425498,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,2]],"date-time":"2027-02-02T00:00:00Z","timestamp":1801526400000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R61AI169199"],"award-info":[{"award-number":["R61AI169199"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM131923"],"award-info":[{"award-number":["R35GM131923"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61\/R33"],"award-info":[{"award-number":["R61\/R33"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1310OD030263 -01"],"award-info":[{"award-number":["1310OD030263 -01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128281","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:13:06Z","timestamp":1770037986000},"page":"128281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A point-mutated Ag85B antigen improves recombinant bacterial expression and protects mice from aerosol M. tuberculosis challenge"],"prefix":"10.1016","volume":"76","author":[{"given":"Wen-Ling","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hvasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennen T.","family":"Troyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kuhlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Obregon-Henao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan F.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128281_bb0005","series-title":"Global tuberculosis report","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128281_bb0010","first-page":"698","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis","volume":"271","author":"Colditz","year":"1994","journal-title":"Meta-analysis of the published literature JAMA"},{"key":"10.1016\/j.vaccine.2026.128281_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1006\/jmbi.2001.4461","article-title":"An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the mycobacterium tuberculosis 30 kda major secretory protein (antigen 85B), a mycolyl transferase11Edited by I","volume":"307","author":"Anderson","year":"2001","journal-title":"A Wilson J Mol Biol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0020","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","article-title":"The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults","volume":"181","author":"Abel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2026.128281_bb0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm0896-893","article-title":"Immunogenicity and protective efficacy of a tuberculosis DNA vaccine","volume":"2","author":"Huygen","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128281_bb0030","doi-asserted-by":"crossref","first-page":"11409","DOI":"10.1038\/s41598-019-47657-9","article-title":"Ensilication improves the thermal stability of the tuberculosis antigen Ag85b and an Sbi-Ag85b vaccine conjugate","volume":"9","author":"Wahid","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128281_bb0035","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11095-009-9995-y","article-title":"Rational design of multiple TB antigens TB10.4 and TB10.4-Ag85B as subunit vaccine candidates against mycobacterium tuberculosis","volume":"27","author":"Shi","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2026.128281_bb0040","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/CVI.00151-06","article-title":"DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB\/c mice","volume":"13","author":"Teixeira","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0045","article-title":"Immunotherapeutic effects of different doses of mycobacterium tuberculosis ag85a\/b DNA vaccine delivered by electroporation","volume":"13","author":"Liang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0050","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.vaccine.2004.07.036","article-title":"A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with mycobacterium tuberculosis and boosts BCG-induced protective immunity","volume":"23","author":"Derrick","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128281_bb0055","doi-asserted-by":"crossref","first-page":"1188754","DOI":"10.3389\/fimmu.2023.1188754","article-title":"Protective RNA nanovaccines against Mycobacterium avium subspecies hominissuis","volume":"14","author":"Touray","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0060","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1016\/j.vaccine.2009.08.018","article-title":"Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against mycobacterium tuberculosis in mice","volume":"27","author":"Luo","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128281_bb0065","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1128\/IAI.69.5.2773-2778.2001","article-title":"Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6","volume":"69","author":"Weinrich Olsen","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128281_bb0070","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/274346","article-title":"Expression and immunogenicity of the mycobacterial Ag85B\/ESAT-6 antigens produced in transgenic plants by elastin-like peptide fusion strategy","volume":"2010","author":"Floss","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0075","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1086\/586902","article-title":"Efficacy of recombinant bacille Calmette-Guerin vaccine secreting interleukin-15\/antigen 85B fusion protein in providing protection against mycobacterium tuberculosis","volume":"197","author":"Tang","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128281_bb0080","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2011.07.039","article-title":"Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis","volume":"29","author":"Ballester","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128281_bb0085","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.vaccine.2012.11.075","article-title":"Enhancement of immune response to a DNA vaccine against mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system","volume":"31","author":"Meerak","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128281_bb0090","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2147\/IJN.S172391","article-title":"Single-dose Ag85B-ESAT6-loaded poly(lactic-co-glycolic acid) nanoparticles confer protective immunity against tuberculosis","volume":"14","author":"Malik","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.vaccine.2026.128281_bb0095","doi-asserted-by":"crossref","first-page":"1306449","DOI":"10.3389\/fimmu.2023.1306449","article-title":"Mucosal and systemic immune responses after a single intranasal dose of nanoparticle and spore-based subunit vaccines in mice with pre-existing lung mycobacterial immunity","volume":"14","author":"Vergara","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0100","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2017.12.016","article-title":"Nanoparticle-fusion protein complexes protect against mycobacterium tuberculosis infection","volume":"26","author":"Hart","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2026.128281_bb0105","article-title":"Evaluation of PLGA, lipid-PLGA hybrid nanoparticles, and cationic pH-sensitive liposomes as tuberculosis vaccine delivery systems in a mycobacterium tuberculosis challenge mouse model - a comparison","volume":"124842","author":"Szachniewicz","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2026.128281_bb0110","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128281_bb0115","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41565-018-0271-3","article-title":"A malaria vaccine adjuvant based on recombinant antigen binding to liposomes","volume":"13","author":"Huang","year":"2018","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-020-0173-x","article-title":"Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment","volume":"5","author":"Huang","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128281_bb0125","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12936-020-03368-5","article-title":"Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose","volume":"19","author":"Huang","year":"2020","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128281_bb0130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s42003-022-03688-z","article-title":"Vaccine co-display of CSP and Pfs230 on liposomes targeting two plasmodium falciparum differentiation stages","volume":"5","author":"Huang","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0135","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.vaccine.2019.10.073","article-title":"Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes","volume":"38","author":"Federizon","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128281_bb0140","article-title":"SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination","volume":"32","author":"Huang","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.vaccine.2026.128281_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304534","article-title":"SARS-CoV-2 protein nanoparticle vaccines formed in situ from lyophilized lipids","volume":"20","author":"Jiao","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.vaccine.2026.128281_bb0150","doi-asserted-by":"crossref","first-page":"10103","DOI":"10.1021\/acsnano.4c16865","article-title":"50-fold adjuvant and 20-fold antigen vaccine dose sparing from Nanoliposome display of a stabilized malarial protein antigen","volume":"19","author":"Song","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2026.128281_bb0155","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12916-022-02661-1","article-title":"Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine","volume":"20","author":"Lovell","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2026.128281_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29927","article-title":"Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a phase 3 randomized, observer-blind, immunobridging trial in the Philippines","volume":"96","author":"Lovell","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0165","first-page":"13","article-title":"Year-Long antibody response to the EuCorVac-19 SARS-CoV-2 vaccine in healthy Filipinos","author":"Lovell","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128281_bb0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijid.2023.11.004","article-title":"One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects","volume":"138","author":"Lovell","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128281_bb0175","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","article-title":"Putting endotoxin to work for us: monophosphoryl lipid a as a safe and effective vaccine adjuvant","volume":"65","author":"Casella","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vaccine.2026.128281_bb0180","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/SHK.0000000000000042","article-title":"The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants","volume":"40","author":"Bohannon","year":"2013","journal-title":"Shock"},{"key":"10.1016\/j.vaccine.2026.128281_bb0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines."},{"key":"10.1016\/j.vaccine.2026.128281_bb0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","article-title":"Structure-based vaccine antigen design","volume":"70","author":"Graham","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2026.128281_bb0195","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128281_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2022.102385","article-title":"Protein engineering responses to the COVID-19 pandemic","volume":"74","author":"Hsieh","year":"2022","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0205","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.immuni.2022.07.015","article-title":"Vaccination with a structure-based stabilized version of malarial antigen Pfs48\/45 elicits ultra-potent transmission-blocking antibody responses","volume":"55","author":"McLeod","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128281_bb0210","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2314853121","article-title":"Transfer learning to leverage larger datasets for improved prediction of protein stability changes","volume":"121","author":"Dieckhaus","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128281_bb0215","first-page":"11","article-title":"Intranasal immunization with liposome-displayed receptor-binding domain induces mucosal immunity and protection against SARS-CoV-2","author":"Huang","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2026.128281_bb0220","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3389\/fimmu.2017.01262","article-title":"Polyfunctional CD4(+) T cells as targets for tuberculosis vaccination","volume":"8","author":"Lewinsohn","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0225","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.vaccine.2011.02.010","article-title":"Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells","volume":"29","author":"Derrick","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128281_bb0230","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4049\/jimmunol.1200061","article-title":"IFN-gamma from CD4 T cells is essential for host survival and enhances CD8 T cell function during mycobacterium tuberculosis infection","volume":"190","author":"Green","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0235","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature04790","article-title":"Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells","volume":"441","author":"Williams","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128281_bb0240","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coi.2014.06.003","article-title":"Defining features of protective CD4 T cell responses to mycobacterium tuberculosis","volume":"29","author":"Sakai","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193596","article-title":"Ag85-focused T-cell immune response controls Mycobacterium avium chronic infection","volume":"13","author":"Cerqueira-Rodrigues","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128281_bb0250","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1086\/592450","article-title":"A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers","volume":"198","author":"Hoft","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128281_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24020966","article-title":"The induction of antigen 85B-specific CD8(+) T cells by recombinant BCG protects against mycobacterial infection in mice","volume":"24","author":"Komine-Aizawa","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.128281_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0322147","article-title":"Efficacy and immunogenicity of rKVAC85B in a BCG prime-boost regimen against H37Rv and HN878 mycobacterium tuberculosis strains","volume":"20","author":"Shin","year":"2025","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128281_bb0265","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1128\/iai.63.5.1710-1717.1995","article-title":"Purification and characterization of a low-molecular-mass T-cell antigen secreted by mycobacterium tuberculosis","volume":"63","author":"Sorensen","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128281_bb0270","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/IAI.68.1.214-220.2000","article-title":"Comparative evaluation of low-molecular-mass proteins from mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens","volume":"68","author":"Skjot","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128281_bb0275","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/jb.178.9.2498-2506.1996","article-title":"Definition of the full extent of glycosylation of the 45-kilodalton glycoprotein of mycobacterium tuberculosis","volume":"178","author":"Dobos","year":"1996","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2026.128281_bb0280","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1128\/IAI.66.9.4208-4214.1998","article-title":"Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by mycobacterium tuberculosis","volume":"66","author":"Webb","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128281_bb0285","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/IAI.67.6.2941-2950.1999","article-title":"Molecular characterization and human T-cell responses to a member of a novel mycobacterium tuberculosis mtb39 gene family","volume":"67","author":"Dillon","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128281_bb0290","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:46:44Z","timestamp":1775195204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":58,"alternative-id":["S0264410X26000897"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128281","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A point-mutated Ag85B antigen improves recombinant bacterial expression and protects mice from aerosol M. tuberculosis challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128281"}}